10q10k10q10k.net
Stereotaxis, Inc.

Stereotaxis, Inc.STXSEarnings & Financial Report

NYSE

Stereotaxis Inc. is an American publicly traded medical technology company based in St. Louis, Missouri, that makes robotic systems used by physicians to perform minimally-invasive endovascular procedures, including electrophysiology studies and cardiac catheter ablation procedures.

STXS Q3 2025 Key Financial Metrics

Revenue

$7.5M

Gross Profit

$4.1M

Operating Profit

$-6.6M

Net Profit

$-6.5M

Gross Margin

54.9%

Operating Margin

-87.8%

Net Margin

-86.6%

YoY Growth

-18.8%

EPS

$-0.07

Financial Flow

Stereotaxis, Inc. Q3 2025 Financial Summary

Stereotaxis, Inc. reported revenue of $7.5M for Q3 2025, with a net profit of $-6.5M (-86.6% margin). Cost of goods sold was $3.4M, operating expenses totaled $10.7M.

Key Financial Metrics

Total Revenue$7.5M
Net Profit$-6.5M
Gross Margin54.9%
Operating Margin-87.8%
Report PeriodQ3 2025

Stereotaxis, Inc. Annual Revenue by Year

Stereotaxis, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $26.9M).

YearAnnual Revenue
2024$26.9M
2023$26.8M
2022$28.1M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$4.6M$6.9M$4.5M$9.2M$6.3M$7.5M$8.8M$7.5M
YoY Growth-37.5%5.1%-42.7%17.9%38.9%8.6%95.4%-18.8%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$41.9M$39.5M$36.0M$50.9M$46.7M$45.7M$41.2M$45.6M
Liabilities$20.0M$19.4M$19.3M$34.7M$35.3M$37.5M$34.4M$34.1M
Equity$16.3M$14.6M$11.4M$10.8M$6.1M$2.9M$1.5M$6.3M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-2.4M$-2.3M$-3.1M$-4.3M$1.3M$-1.8M$-3.7M$-4.2M